Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial - Telli, M; Turner, N; Mailliez, A (Cancer Res, 2018)